Hikma Slams Amarin In Vascepa Antitrust Suit For ‘Locking Up API Supply’
Fellow Icosapent ANDA Sponsor Dr Reddy’s Also Previously Filed Antitrust Suit
Amarin is facing up to another antitrust lawsuit over its alleged control of API supply for its Vascepa brand.
You may also be interested in...
Strides intends to keep US momentum going with Amneal-partnered generic Vascepa, where Hikma and Dr. Reddy’s have filed antitrust suits against Amarin over API supply. Meanwhile, the founder re-iterated ambitious goals set for Stelis and its CDMO business
Amneal has in-licensed Strides’ generic version of Vascepa to compete with the several ANDA products already on the market.
Amarin’s management has suggested that it would be prepared to compete “very aggressively” with a US authorized generic version of its Vascepa if and when it decides to launch. The comments came as the originator named a new CEO and restructured in the wake of increasing generic competition.